PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2798988

[Systemic cardiorespiratory effects induced by doxofylline].

G F Bagnato·A Allegra·A De Leo·M S Giacobbe·A Mileto·M Cinquegrani·G Leotta·A L Buemi·E Spina·M Scibilia
View original source ↗Export metadata ↓

Abstract

The authors evaluated the clinical effectiveness and tolerability of doxofylline, a new methyl-xanthinic derivative with peculiar pharmacodynamic properties. 13 patients affected with chronic obstructive lung disease (mean age +/- 54 years) were studied. Doxofylline (200 mg) and theophylline (240 mg) were randomly administered by intravenous route in 60'. Arterial haemogasanalysis, FEV1 and ECG data were obtained after the infusion. Doxofylline proved to possess an equal therapeutic efficacy in comparison to theophylline, with a better clinical tolerability. In conclusion, doxofylline is a new and effective drug for the treatment of bronchostructive disorders.

Explore related subjects

Cardiovascular SystemFemaleHumansMaleMiddle AgedRespirationRespiratory Function TestsTheophyllineEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G F Bagnato, A Allegra, A De Leo, M S Giacobbe, A Mileto, M Cinquegrani, G Leotta, A L Buemi, E Spina, M Scibilia. 1989. [Systemic cardiorespiratory effects induced by doxofylline].. https://pubmed.ncbi.nlm.nih.gov/2798988/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Sleep apnoea and hypertension: role of chemoreflexes in humans.

The link between sleep apnoea and systemic hypertension in humans is well documented. However, a direct causal association between the two diseases independent of comorbidities has been difficult to establish. Comorbidities clearly play an important role in this strong relationship; however, new findings also suggest that sleep apnoea is an independent risk factor for hypertension. This relationship appears to be at least in part a result of chronically elevated sympathetic activity, and therefore manifests as a neurally mediated hypertension. Although the mechanism(s) for this causal relationship of sleep apnoea to hypertension remains ill defined, a growing body of literature suggests that autonomic dysfunction, mediated by abnormal chemoreflex control of sympathetic activity, is a potential mechanism. Abnormal chemoreflex responses to both acute and chronic apnoea or hypoxia have been demonstrated. Hypothesized mechanisms by which chemoreflex dysfunction may contribute to chronically elevated sympathetic tone and ultimately hypertension are explored in this review. Thus, this review focuses on the current evidence linking chemoreflex function to obstructive sleep apnoea and systemic hypertension in humans and provides an analysis of these data and their implications.

Cardiovascular System↗
PubMed2006

Gender differences in drug responses.

This review summarizes gender differences (GDs) in drug response. Although GDs have been described both in pharmacodynamics and pharmacokinetics, their role in clinical practice is not yet completely elucidated. The evidence that women have been less enrolled in clinical trials and that a gender-specific analysis usually is not included in the evaluation of results, contributes largely to this uncertainty. Consequently, adverse drug reactions (ADRs) are still higher in females than in males. Since sex is a fundamental biological variable that cannot be discounted, GDs in pharmacology have to be considered in order to improve drug safety efficacy and to optimize medical therapy both in men and women.

Cardiovascular System↗